New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
November 20, 2009
10:59 EDTBIIB
theflyonthewall.com: HealthCor sends letter to Biogen Idec board
An excerpt of the letter follows: In this letter, we highlight three areas where we are particularly isappointed with the Company: 1) The disconnect between James Mullen's compensation and Biogen Idec's stock performance; 2) The lack of a consistent commitment to return cash to shareholders; and 3) The Company's excessive and fruitless Research and Development spend. We ask the Board to take swift action to remedy our concerns, which we believe will result in an immediate and meaningful creation of shareholder value. :theflyonthewall.com



News For BIIB From The Last 14 Days
Check below for free stories on BIIB the last two weeks.
There are 10 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 6, 2012
08:22 EDTBIIB
theflyonthewall.com: Biogen investigated for sales and promotional practices, WSJ reports

Subscribe for More Information :theflyonthewall.com

January 31, 2012
11:21 EDTBIIB
theflyonthewall.com: Piper Jaffray's biotech and specialty pharma analysts hold a conference call

Subscribe for More Information :theflyonthewall.com
07:03 EDTBIIB
theflyonthewall.com: Biogen reports Q4 global in-market sales of TYSABRI $380M
Based upon data available to us through the TOUCH® prescribing program and other third-party sources, as of the end of December 2011, the company estimates that approximately 64,400 patients were on commercial and clinical TYSABRI therapy worldwide, and that cumulatively approximately 95,300 patients have ever been treated with TYSABRI in the post-marketing setting. :theflyonthewall.com
07:03 EDTBIIB
theflyonthewall.com: Biogen sees FY12 CapEx $230M-$250M

Subscribe for More Information :theflyonthewall.com
07:03 EDTBIIB
theflyonthewall.com: Biogen sees FY12 adjusted EPS $6.10-$6.20 vs. consensus $6.32

Subscribe for More Information :theflyonthewall.com
07:02 EDTBIIB
theflyonthewall.com: Biogen reports Q4 adjusted EPS $1.51 vs. consensus $1.49

Subscribe for More Information :theflyonthewall.com

January 30, 2012
11:44 EDTBIIB
theflyonthewall.com: Leerink's biotech and pharmaceuticals analysts hold a conference call

Subscribe for More Information :theflyonthewall.com

January 26, 2012
23:33 EDTBIIB
theflyonthewall.com: Jim Cramer's "Mad Money"

Subscribe for More Information :theflyonthewall.com
11:09 EDTBIIB
theflyonthewall.com: Leerink's biotech and pharmaceuticals analysts hold a conference call

Subscribe for More Information :theflyonthewall.com
08:03 EDTBIIB
theflyonthewall.com: Biogen, Elan announce Phase 3b ASCEND trial for TYSABRI
Biogen Idec (BIIB) and Elan Corporation (ELN) announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for secondary-progressive multiple sclerosis. A global study, ASCEND is expected to enroll approximately 850 patients in 15 countries. The primary endpoint is to investigate whether treatment with TYSABRI slows the accumulation of disability not related to relapses in subjects with SPMS. :theflyonthewall.com